StockpollyBeta
Get App
Popularity #1,687
ABEO · NASDAQ · Biotechnology

Abeona Therapeutics (ABEO)

Commercializes ZEVASKYN for RDEB wounds through qualified treatment centers.

$5.56
vs last close−0.27 (−4.55%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000005911
Cost of revenue010001000344
Gross profit0−1000−1000357
111214181516202324252821
Research & development77799910647105
457967101719191916
General & administrative40796010171919016
Operating income−11−13−14−18−15−17−20−23−24−23−23−14
−1−3−1725−1578147426−7
Interest income111111112211
Interest expense001111111111
Other non-operating income0316−2614−8−9−148−5−3−76
Income before tax−12−17−327−30−9−12124−20−21−17−20
Income tax expense000000016−15000
Net income from continuing operations−12−17−327−30−9−12109−5−20−17−20
Net income−12−17−327−30−9−12109−5−20−17−20
EPS, basic−$0.48−$0.65−$1.16$0.19−$0.63−$0.23−$0.24$2.07−$0.10−$0.39−$0.30−$0.35
EPS, diluted−$0.48−$0.65−$1.16$0.14−$0.63−$0.23−$0.24$1.71−$0.10−$0.36−$0.30−$0.35
Weighted average shares, basic252627404841505354535757
Weighted average shares, diluted252627514841506754665757
EBITDA−11−16−309−28−7−10126−19−19−15−19
Depreciation & amortization111111111111
EBIT−12−16−318−29−8−11125−19−20−16−19